Grilled Cheese

ExploreLog inSign up
Terms of UsePrivacy PolicyCommunity StandardsHelpGet the app

Grilled Cheese is a product of Village Compute

Version devBuilt at: 2026-10-11 02:37:10 EDT

Explore

PostsPeople
LatestRanked
@herzmedizin.bsky.socialOct 9, 2026, 10:02 AM

✨ #EASDCongress 2026: Kardiovaskuläre Sicherheit von #Orforglipron
🔬 Studie: ACHIEVE 4
🎙️ Präsentiert von: Prof. K. Klein
🔍 Prof. N. Marx (Universitätsklinikum Aachen) ordnet die neuen Daten zur kardiovaskulären Risikoreduktion ein.
➡️ herzmedizin.de/fuer-aerzte-...
#DGK #Kardiologie #CardioSky

@dgk-org.bsky.socialOct 8, 2026, 8:46 AM

✨ #EASDCongress 2026: Kardiovaskuläre Sicherheit von #Orforglipron
🔬 Studie: ACHIEVE 4
🎙️ Präsentiert von: Prof. K. Klein
🔍 Prof. N. Marx (Universitätsklinikum Aachen) ordnet die neuen Daten zur kardiovaskulären Risikoreduktion ein.
➡️ herzmedizin.de/fuer-aerzte-...
#DGK #Kardiologie #CardioSky

@midgardfinance.comOct 2, 2026, 12:30 PM

💊 #pharma #EASD2026

🇺🇸 $LLY #orforglipron on major heart events vs insulin: hazard ratio 0.77 (0.52-1.13). Too small a trial to prove a benefit.

Not head to head: tirzepatide 0.92 vs dulaglutide; 🇩🇰 $NOVO #semaglutide pill 0.86, injection 0.80 vs placebo.

midgardfinance.com/cardiovascular/

Forest plot of hazard ratios for major heart events (heart attack, stroke or cardiovascular death) in four outcome trials of incretin drugs, on a log axis with a vertical line at 1; left of the line means fewer events than the comparison arm. The rows are in two groups because the trials were run against different things. Tested against placebo, in light blue: Semaglutide injection against placebo (SELECT, 17,604 patients): 0.80, interval 0.72 to 0.90. Semaglutide pill against placebo (SOUL, 9,650 patients): 0.86, interval 0.77 to 0.96. Tested against another drug, in purple: Tirzepatide against dulaglutide (SURPASS-CVOT, 13,299 patients): 0.92, interval 0.83 to 1.01. Orforglipron pill against insulin glargine (ACHIEVE-4, 2,749 patients): 0.77, interval 0.52 to 1.13. Orforglipron's estimate lies among the others, but its interval is about 4 times as wide and crosses 1: its trial was sized to rule out harm, which it did, not to prove a benefit. These are separate trials, not head-to-head comparisons. Dulaglutide is itself a heart-protective drug, so a ratio against it cannot be set beside a ratio against placebo, and SELECT enrolled people without diabetes while the other three enrolled people with type 2 diabetes. For orforglipron this is the three-part endpoint; its primary endpoint, which also counts hospitalisation for unstable angina, was 0.84 with an interval of 0.59 to 1.20.
@midgardfinance.comOct 1, 2026, 2:00 PM

💊 #pharma #EASD2026

🇺🇸 $LLY #orforglipron, a daily pill, vs insulin glargine in type 2 diabetes at high CV risk (ACHIEVE-4, n=2,749): major CV events HR 0.84 (0.59-1.20). Non-inferior, not shown better.

Deaths HR 0.43 (0.25-0.75), not a formally tested endpoint.

midgardfinance.com/diabetes/

Forest plot titled "Orforglipron pill vs insulin glargine", from Lilly's ACHIEVE-4 trial in 2,749 adults with type 2 diabetes, obesity or overweight and raised cardiovascular risk. Four hazard ratios with 95% intervals on a log axis from 0.2 to 2, with a vertical line at 1; below 1 favours the pill. MACE-4 (primary): 0.84 (0.59-1.20). MACE-3: 0.77 (0.52-1.13). Cardiovascular death: 0.47 (0.25-0.90). Death, any cause: 0.43 (0.25-0.75). The first two, drawn in grey, were the tested endpoints and their intervals cross 1: the pill met non-inferiority (limit 1.8) and was not shown to be better. The two death endpoints, in purple, sit below 1 but were not controlled for multiple testing. Open-label trial, median follow-up two years; the primary endpoint occurred in 57 of 1,358 on the pill and 67 of 1,343 on insulin. At week 52, counting all randomised patients, HbA1c fell 1.5 points on the pill and 1.0 on insulin; weight changed -7.8% and +1.1%.
@thelancetendo.bsky.socialOct 1, 2026, 7:42 AM

In @thelancet.com

Cardiovascular safety of #orforglipron versus insulin glargine in adults with type 2 #diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial
www.thelancet.com/journals/lan...
#T2D
#EASD2026

@gmj-georgia.bsky.socialSep 24, 2026, 11:27 PM

🔬 Breakthrough in weight-loss pharmacotherapy: Orforglipron, a new once-daily oral tablet, has outperformed semaglutide in a major cl… #Clinicaltrial #Globalhealthaccess #GLP1agonists #Orforglipron #Pharmaceuticalinnovation #Clinicaltrial #Globalhealthaccess #GLP1agonists #Orforglipron #Pharmac…